This clinical trial is focused on studying the treatment of COVID-19, a respiratory infection caused by the SARS-CoV-2 virus. The trial will evaluate a new medication called S-217622, which is a type of drug known as a protease inhibitor. Protease inhibitors work by blocking a specific enzyme that the virus needs to multiply, potentially helping to reduce the severity of the infection. Participants in the study will receive either the S-217622 medication or a Placebo-B, which is a substance with no active ingredients, alongside the standard care they would normally receive in the hospital.

The purpose of this study is to determine if a 5-day treatment with S-217622 can improve the clinical outcomes for patients hospitalized with COVID-19. The study will involve patients who are admitted to the hospital with symptoms of a respiratory infection and have confirmed COVID-19. The trial will monitor participants over a period of 60 days to assess their recovery and overall health status. The main focus will be on how quickly patients recover, as well as their health condition at the end of the study period.

Throughout the study, researchers will also keep track of any serious health events or side effects that may occur. This will help ensure the safety of the participants and provide valuable information about the potential benefits and risks of using S-217622 as a treatment for COVID-19. The trial aims to provide insights into whether this new medication can be an effective addition to the current treatment options for hospitalized patients with COVID-19.